Amarillo, Texas, May 17, 2010 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced additional positive results from a Phase 2 clinical trial conducted at the University of Western Australia. A total of 200 healthy volunteers were enrolled in this study to take a once daily dose of oral interferon or placebo for 16 weeks as prevention of influenza-like illness during the 2009 Australian cold and flu season.  Blood samples collected from the volunteers at the beginning and end of treatment were tested for evidence of infection with seven common respiratory viruses, including influenza virus A and B; parainfluenza virus 1, 2 and 3; adenovirus; and respiratory syncytial virus (RSV).

Amarillo, Texas, April 9, 2010 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia has submitted a final report on the recently completed 200 subject low-dose oral interferon (IFN) Phase 2 clinical trial in Perth, Australia. Dr. Beilharz was one of two principal investigators of the study for which ABI provided the oral interferon.  The report, sent to the State Health Research Advisory Council of the Department of Health, Western Australia (DOH WA) evaluated the drug’s safety and efficacy in combating colds and influenza.  The report is available on ABI’s website (http://www.amarbio.com/Download-document/20-Australian-Influenza-Study-Report.html).